HER-2 Positive Breast Cancer Recruiting Phase 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0042425 (HER-2 Positive Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02598310Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast CancerTreatment